{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/MAZE/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-29T19:18:35.483Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":4645,"canonical_name":"Maze Therapeutics, Inc.","cik":"0001842295","uei":null,"lei":null,"duns":null,"ticker":"MAZE"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":38},"count":38,"timeline":[{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Maze Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001842295/10-q/0001193125-26-344903","accession_number":"0001193125-26-344903","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Maze Therapeutics, Inc. — 2026-08-11","url_slug":"/sec/cik-0001842295/8-k/0001193125-26-344878","accession_number":"0001193125-26-344878","importance":35},{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Maze Therapeutics, Inc. — 2026-07-02","url_slug":"/sec/cik-0001842295/4/0002050172-26-000025","accession_number":"0002050172-26-000025","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"HAROLD BERNSTEIN","title":"Officer","shares":46892,"usd_value":1399257,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006773","importance":40.279851456},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":30311,"price_per_share":29.9535,"usd_value":907921,"security_title":"Common Stock","importance":35.9079205385},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":13409,"price_per_share":29.865,"usd_value":400460,"security_title":"Common Stock","importance":35.400459785},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":2593,"price_per_share":29.9754,"usd_value":77726,"security_title":"Common Stock","importance":35.0777262122},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":1597,"price_per_share":30.4359,"usd_value":48606,"security_title":"Common Stock","importance":35.0486061323},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":1200,"price_per_share":30.3369,"usd_value":36404,"security_title":"Common Stock","importance":35.03640428},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Maze Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001842295/144/0001950047-26-006773","accession_number":"0001950047-26-006773","importance":30},{"ts":"2026-07-01","kind":"sec.filing","form_type":"4","title":"4 — Maze Therapeutics, Inc. — 2026-07-01","url_slug":"/sec/cik-0001842295/4/0002050167-26-000016","accession_number":"0002050167-26-000016","importance":30},{"ts":"2026-07-01","kind":"sec.insider.m","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":14609,"price_per_share":10.42,"usd_value":152226,"security_title":"Common Stock","importance":15.15222578},{"ts":"2026-06-29","kind":"sec.insider.s","reporter":"Dandekar Atul","title":"CSBO","shares":7500,"price_per_share":28.02,"usd_value":210150,"security_title":"Common Stock","importance":35.21015},{"ts":"2026-06-29","kind":"sec.insider.m","reporter":"Dandekar Atul","title":"CSBO","shares":7500,"price_per_share":10.42,"usd_value":78150,"security_title":"Common Stock","importance":15.07815},{"ts":"2026-06-23","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":23865,"price_per_share":26.0496,"usd_value":621674,"security_title":"Common Stock","importance":35.621673704},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":2040,"price_per_share":26,"usd_value":53040,"security_title":"Common Stock","importance":35.05304},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":1953,"price_per_share":26.0015,"usd_value":50781,"security_title":"Common Stock","importance":35.0507809295},{"ts":"2026-06-10","kind":"sec.filing","form_type":"8-K","title":"8-K — Maze Therapeutics, Inc. — 2026-06-10","url_slug":"/sec/cik-0001842295/8-k/0001193125-26-265858","accession_number":"0001193125-26-265858","importance":35},{"ts":"2026-06-03","kind":"sec.filing","form_type":"4","title":"4 — Maze Therapeutics, Inc. — 2026-06-03","url_slug":"/sec/cik-0001842295/4/0002050172-26-000023","accession_number":"0002050172-26-000023","importance":30},{"ts":"2026-06-02","kind":"sec.filing","form_type":"4","title":"4 — Maze Therapeutics, Inc. — 2026-06-02","url_slug":"/sec/cik-0001842295/4/0002050167-26-000013","accession_number":"0002050167-26-000013","importance":30},{"ts":"2026-06-01","kind":"sec.form144","reporter":"Coloma Jason V","title":"Officer","shares":34501,"usd_value":908066,"security_title":"Common","approx_sale_date":"2026-06-01","accession_number":"0001969223-26-000612","importance":40.181613264},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":13253,"price_per_share":25.5746,"usd_value":338940,"security_title":"Common Stock","importance":35.3389401738},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":6090,"price_per_share":26.1965,"usd_value":159537,"security_title":"Common Stock","importance":35.159536685},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":1600,"price_per_share":26.3576,"usd_value":42172,"security_title":"Common Stock","importance":35.04217216},{"ts":"2026-06-01","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":553,"price_per_share":26.2412,"usd_value":14511,"security_title":"Common Stock","importance":35.0145113836},{"ts":"2026-06-01","kind":"sec.insider.m","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":14853,"price_per_share":10.42,"usd_value":154768,"security_title":"Common Stock","importance":15.15476826},{"ts":"2026-05-29","kind":"sec.insider.s","reporter":"Dandekar Atul","title":"CSBO","shares":7500,"price_per_share":26.3405,"usd_value":197554,"security_title":"Common Stock","importance":35.19755375},{"ts":"2026-05-29","kind":"sec.insider.m","reporter":"Dandekar Atul","title":"CSBO","shares":7500,"price_per_share":10.42,"usd_value":78150,"security_title":"Common Stock","importance":15.07815},{"ts":"2026-05-18","kind":"sec.filing","form_type":"4","title":"4 — Maze Therapeutics, Inc. — 2026-05-18","url_slug":"/sec/cik-0001842295/4/0002050172-26-000021","accession_number":"0002050172-26-000021","importance":30},{"ts":"2026-05-15","kind":"sec.form144","reporter":"Coloma Jason V","title":"Officer","shares":34502,"usd_value":895327,"security_title":"Common","approx_sale_date":"2026-05-15","accession_number":"0001969223-26-000561","importance":40.17906538},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":1822,"price_per_share":26,"usd_value":47372,"security_title":"Common Stock","importance":35.047372},{"ts":"2026-05-15","kind":"sec.insider.s","reporter":"Coloma Jason V","title":"Chief Executive Officer","shares":116,"price_per_share":26,"usd_value":3016,"security_title":"Common Stock","importance":35.003016},{"ts":"2026-05-14","kind":"sec.insider.s","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":15000,"price_per_share":26.2236,"usd_value":393354,"security_title":"Common Stock","importance":35.393354},{"ts":"2026-05-14","kind":"sec.insider.m","reporter":"Bernstein Harold","title":"President, R&D & CMO","shares":15000,"price_per_share":10.42,"usd_value":156300,"security_title":"Common Stock","importance":15.1563},{"ts":"2026-05-13","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Maze Therapeutics, Inc. — 2026-05-13","url_slug":"/sec/cik-0001842295/effect/9999999995-26-001606","accession_number":"9999999995-26-001606","importance":30},{"ts":"2026-05-12","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Maze Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001842295/10-q/0001193125-26-219430","accession_number":"0001193125-26-219430","importance":45},{"ts":"2026-05-12","kind":"sec.filing","form_type":"8-K","title":"8-K — Maze Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001842295/8-k/0001193125-26-219398","accession_number":"0001193125-26-219398","importance":35},{"ts":"2026-05-12","kind":"sec.filing","form_type":"POS AM","title":"POS AM — Maze Therapeutics, Inc. — 2026-05-12","url_slug":"/sec/cik-0001842295/pos-am/0001193125-26-219386","accession_number":"0001193125-26-219386","importance":30}]}